News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LXRX under $2
Still looking pretty good here. Did trim a few 2.38's thouigh. Not sure if we'll see a reset soon or not.
Ready to see this rock and roll. Get the Christmas rally going!
https://www.inpefahcp.com/
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. Wikipedia
Stock price: LXRX (NASDAQ) $1.16 +0.01 (+1.32%)
Dec 6, 10:18?AM EST - Disclaimer
Headquarters: The Woodlands, TX
CEO: Lonnel Coats (Jul 7, 2014–)
Revenue: 324.1 million USD (2019)
Number of employees: 225 (2011)
Founded: 1995, The Woodlands, TX
Founder: Arthur T Sands
Subsidiaries: Lex-Gen Woodlands, L.P., Lexicon Pharmaceuticals (New Jersey), Inc
Product
https://www.lexpharma.com/
https://www.lexpharma.com/media-center/news
Insider buying... Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc
https://finance.yahoo.com/news/director-philippe-amouyals-strategic-200-060356510.html?guccounter=1&guce_referrer=aHR0cHM6Ly9maW52aXouY29tLw&guce_referrer_sig=AQAAAIoi6pMjBlhAAWCTqsgFDgJ_L3Mq27MaOD9VoCvqo193rq8IznDFhr2okgZCfdpTcOoOQpbq-htdQ0dRd_C7SPjLqq1-XLfxoxxNvrWLXCfYfWwGJkWm40NnRnChJ7IS-3NNjcnArKcxghtaIU9gZcRtqotAVRnZUPj9phWfJymM
LXRX new 52 week low
$LXRX. Looking good. See this in a week or 2.
JMHO.
LXRX new 52 week low
LXRX new 52 week low
LXRX new 52 week low
Quite the boost for institutionals.
https://www.sec.gov/Archives/edgar/data/1062822/000119312523160877/d449914dsc13da.htm
Hey there Glenn. This puppy has been excellent. Certainly one to keep an eye on.
If I se what I think I see, there's a reason shorts are leaving this puppy alone.
Added back in this morning but when something starts really moving you always say in hindsight that you should have bought more.
High 2.96. Trip and rip potential. That's when the chart show either a tripple bottom or a tripple top and breaks through with some serious momentum.
See what this puppy does.
https://www.barchart.com/stocks/quotes/hils/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=LXRX&grid=1&height=210&studyheight=100
Passing 2.69.
Let's get the move on.
PUDUFA coming in a couple months. Looks like they're pretty confident.
GLTA
|
Followers
|
56
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
781
|
|
Created
|
02/27/05
|
Type
|
Free
|
| Moderators | |||
Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies
THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.
In the SOLOIST study, the primary endpoint was achieved with a hazard ratio (HR) of 0.67 (p<0.001) in people with type 2 diabetes and a recent hospitalization for worsening heart failure. In the SCORED study, the primary endpoint was achieved with a hazard ratio of 0.74 (p<0.001) in people with type 2 diabetes and chronic kidney disease with an estimated glomerular filtration rate (eGFR) of 25 to 60 ml/minute per 1.73 m² of body-surface area.
The key results from SOLOIST and SCORED were presented today at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The articles may be accessed at www.nejm.org.
“Cardiovascular disease continues to be a leading cause of death in people with type 2 diabetes,” said Deepak L. Bhatt, M.D., M.P.H., executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and a professor of medicine at Harvard Medical School and study chair and lead author for the NEJM publications of the SOLOIST and SCORED results. “SOLOIST demonstrates that early, in-hospital initiation of sotagliflozin in patients with worsening heart failure significantly reduces subsequent cardiovascular events, an effect that was consistent across groups with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). SCORED demonstrates that sotagliflozin significantly reduces heart failure events in a patient population with stage 3 and 4 chronic kidney disease and cardiovascular risk. Both studies add to the evidence that SGLT2 inhibition should be standard of care in heart failure, and the SCORED data reflecting a reduction in myocardial infarction and stroke and better glucose control in CKD patients suggest potential benefits from the dual SGLT1 and SGLT2 mechanism of this particular agent.”
AI
